Low T-cell numbers including limited CD8+ naïve T-cells, as well as an abundance of regulatory T-cells, terminally exhausted CD8+ T-cells, and T-cells expressing CD38+, PD-1, and TIM-3 are associated poorer responses to MM immunotherapy [23, 29]. The gene discussed is CD8A; the disease is Miyoshi myopathy.